Publicaciones en las que colabora con Santiago Muñoz Fernández (36)

2023

  1. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477

2021

  1. Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain

    Reumatologia Clinica, Vol. 17, Núm. 5, pp. 245-249

  2. Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey

    Joint Bone Spine, Vol. 88, Núm. 4

2020

  1. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662

  2. Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377

  3. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 72, Núm. 2, pp. 216-224

2019

  1. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study

    Rheumatology International, Vol. 39, Núm. 12, pp. 2015-2024

  2. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  3. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  4. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 5, pp. 252-257

2018

  1. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

  2. Recommendations for the use of parenteral methotrexate in rheumatic diseases

    Reumatologia Clinica, Vol. 14, Núm. 3, pp. 142-149

  3. Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence

    Rheumatology International, Vol. 38, Núm. 12, pp. 2289-2296

2017

  1. Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort

    Arthritis Care and Research, Vol. 69, Núm. 6, pp. 938-942

  2. Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis

    Arthritis Care and Research, Vol. 69, Núm. 1, pp. 150-155

  3. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

    Arthritis and Rheumatology, Vol. 69, Núm. 2, pp. 362-375

  4. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus

    Seminars in Arthritis and Rheumatism, Vol. 47, Núm. 1, pp. 38-45

2016

  1. Differences between familial and sporadic early spondyloarthritis: Results from the ESPERANZA cohort

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 4, pp. 575-580

  2. Evaluation of the impact of nursing clinics in the rheumatology services

    Rheumatology International, Vol. 36, Núm. 9, pp. 1309-1317

  3. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250